Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial
Ran Reshef(Abramson Cancer Center), David Porter(University of Pennsylvania), James K. Mangan(UC San Diego Health System), Edward A. Stadtmauer(University of Pennsylvania), Robert H. Vonderheide(University of Pennsylvania), Alison W. Loren(University of Pennsylvania), Lisa Crisalli(University of Pennsylvania), Rosemarie Mick(University of Pennsylvania), Robin Blauser(University of Pennsylvania), J. Reed McGraw(University of Pennsylvania), James A. Hoxie(University of Pennsylvania), Noelle V. Frey(Hospital of the University of Pennsylvania), Elizabeth O. Hexner(University of Pennsylvania), Alex Ganetsky(Hospital of the University of Pennsylvania), Edward P. Acosta(University of Alabama at Birmingham), Selina M. Luger(University of Pennsylvania)
Cited by 31
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k